Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Probiotics for Glycemic Control in Type 1 Diabetes
NCT03556631Phase 4Completed
- Sponsor
- Shenzhen People's Hospital
- Start
- Sep 2020
- Primary completion
- Sep 2021
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of bifidobacterium + lactobacillus in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Shenzhen People's Hospital. Primary endpoint: Hemoglobin A1c at 3 months. Started Sep 2020; status: completed.
02
Drugs
bifidobacterium + lactobacillus
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT03556631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03556631.